Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Urba

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Surgical Oncology Clinics of North America|May 14, 2019
Immunotherapy ToxicitiesKatherine Sanchez, David B Page, Walter Urba
Oncoimmunology|December 25, 2012
Radiation and immunotherapy: Renewed allies in the war on cancerSteven K Seung, Brendan Curti, Marka Crittenden, et al.
International Journal of Cancer|January 22, 2004
Targeting and amplification of immune killing of tumor cells by pro-SmacRui Li, Dominik Rüttinger, Walter Urba, et al.
BMC Cancer|March 10, 2016
GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogsBella S Guerrouahen, Tobias Hahn, Zefora Alderman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Phase I/II study of ipilimumab for patients with metastatic melanomaJeffrey S Weber, Steven O'Day, Walter Urba, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
A clinical development paradigm for cancer vaccines and related biologicsAxel Hoos, Giorgio Parmiani, Kristen Hege, et al.
Cancer Informatics|November 28, 2022
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 ImmunotherapyEmma Bigelow, Suchi Saria, Brian Piening, et al.
American Journal of Hematology|February 14, 2020
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphomaJohn Timmerman, Charles Herbaux, Vincent Ribrag, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Surgical Oncology Clinics of North America|May 14, 2019
Immunotherapy ToxicitiesKatherine Sanchez, David B Page, Walter Urba
Oncoimmunology|December 25, 2012
Radiation and immunotherapy: Renewed allies in the war on cancerSteven K Seung, Brendan Curti, Marka Crittenden, et al.
International Journal of Cancer|January 22, 2004
Targeting and amplification of immune killing of tumor cells by pro-SmacRui Li, Dominik Rüttinger, Walter Urba, et al.
BMC Cancer|March 10, 2016
GMP-grade α-TEA lysine salt: a 28-Day oral toxicity and toxicokinetic study with a 28-Day recovery period in Beagle dogsBella S Guerrouahen, Tobias Hahn, Zefora Alderman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Phase I/II study of ipilimumab for patients with metastatic melanomaJeffrey S Weber, Steven O'Day, Walter Urba, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 2, 2007
A clinical development paradigm for cancer vaccines and related biologicsAxel Hoos, Giorgio Parmiani, Kristen Hege, et al.
Cancer Informatics|November 28, 2022
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 ImmunotherapyEmma Bigelow, Suchi Saria, Brian Piening, et al.
American Journal of Hematology|February 14, 2020
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphomaJohn Timmerman, Charles Herbaux, Vincent Ribrag, et al.
Nature Reviews. Clinical Oncology|August 29, 2013
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaHoward L Kaufman, John M Kirkwood, F Stephen Hodi, et al.
Pageof 1